|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to residues C(95) T H S P Y A Q P S S(104) of human p73.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS with 0.2% gelatin|
|Contains||0.05% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Western Blot (WB)||1-3 µg/ml|
This peptide sequence is 100% conserved across multiple p73 isoforms and between rat, mouse, dog and bovine p73.
Suggested positive control: antigen standard for TP73 (transient overexpression lysate), p73 transfected cells.
p73 was identified as a long-lost cousin of tumor suppressor protein, p53 (4). p73 has high homology with p53 as well as with p63, a gene implicated in the maintenance of epithelial stem cells. Significant homology between p53, p63, and p73 (approximately 63% amino acid identity in the DNA-binding domain suggest that they may have overlapping functions in the regulation of gene expression (3). The targeted disruption of p73 gene leads to defects hippocampal dysgenesis, hydrocephalus, chronic inflammation and infections (2). Recently, spilicing variant mRNAs of p73 has been identified in MCF-7, a breast carcinoma cell line. These mRNAs code for variant p73 proteins bearing distinct carboxy-terminal structures suggesting that the carboxy-terminal region of p73 may be important for the functions of this protein (1). Tumor BioMarker: Vella et al (2003) found p73 to be upregulated in a significant fraction of anaplastic thyroid cancers, whereas it was not detectable in normal thyroid epithelial cells nor in papillary or follicular thyroid cancer.
p53-like transcription factor; p53-related protein; P73